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Moderate to severe chronic venous disease
affects more than six million people in the United
States, with an estimated 800,000 new cases report-
ed annually.1,2 More than 75% of these people have
some component of deep involvement, and approx-
imately 85% of these people have insufficiency as the
major pathophysiologic abnormality.2 If 50% of
patients have primary valvular insufficiency,3,4
approximately 2 million people (generally post-
phlebitic) are potential candidates for surgical cor-
rection, other than valvuloplasty, of the offending
venous insufficiency. However, not all patients may
be proper candidates because of either anatomic
abnormalities or the ability of conservative treat-
ments to ameliorate the patient’s symptoms. In an
active venous practice, approximately 10% of post-
phlebitic patients with venous reflux actually have
anatomy amenable to current surgical interven-
tion.5,6 This would suggest that approximately
200,000 people are potential candidates for aggres-
sive surgical therapy, when warranted.
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Valve transposition operations are possible in less
than 5% of all patients considered for surgical inter-
vention.7,8 Only 60% of the remaining patients have
a competent upper-extremity valve available for
transplantation.5 Disregarding that such thin-walled
upper-extremity valves may dilate in time, resulting
in recurrent incompetence,8,9 this would still leave
approximately 40% of postphlebitic patients (more
than 50,000 people) who have chronic venous 
disease and severe symptoms with no appropriate
valve for transplantation. The need for an alternative
valve to act as a substitute for the autogenous valve
becomes obvious.
Generally, off-the-shelf venous valve substitutes
have faired poorly in animal experimentation.10-14
However, a cross-matched cryopreserved venous
valve allograft implanted into a chronic deep venous
insufficiency greyhound model aided by a distal arte-
riovenous fistula (dAVF) has remained patent and
improved venous hemodynamics during a 2-month
period of study.15 The use of a cryopreserved super-
ficial femoral vein valve to replace defective autoge-
nous valves in humans is appealing in two respects.
These valves are accustomed to the hemodynamic
stresses inherent to the lower limb and have a size
and thickness equal to the recipient site. Transition
to clinical trial seemed reasonable, because further
animal study would likely add little to our under-
standing of the allograft, and cryopreserved tissues
are routinely used clinically, eliminating some of the
safety questions we might have otherwise faced.16,17
MATERIALS AND METHODS
The patients chosen to participate had end-stage
chronic deep venous insufficiency and were a very
specific group, which necessitated a multi-institu-
tional research team for timely patient accrual. We
thought that 10 patients would be sufficient to
answer the basic safety and allograft valve function
issues being considered. The primary objective was
to evaluate the ability of a cryopreserved valve con-
taining venous allograft to remain patent and compe-
tent when transplanted as a substitute valve into
patients with isolated chronic lower-extremity deep
venous insufficiency. These were patients who had
essentially no remaining options for correcting the
hemodynamic problem causing their severe symp-
toms (clinical classes 4 to 6).18 The clinical impact
was a secondary end point of this initial safety and
feasibility study. Appropriate patients were recruited
when they came to the participating surgeons’ clinics.
Before patient recruitment, all aspects of this
prospective study were discussed and agreed on by
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the participating investigators. The written protocol,
with consent form, was approved by the respective
institutional review boards. Patients were fully
informed of potential risks, alternative approaches,
and the possible benefit of this surgical treatment
before studies that would not have been required for
a standard autogenous valve transplantation proce-
dure were obtained.
Preoperative assessment
Clinical inclusion criteria. Patients were restrict-
ed to those with class 4 or higher signs of chronic
deep venous insufficiency18 that were lifestyle dis-
abling, even with appropriate conservative medical
treatment. The etiology was primary valvular incom-
petence or of a secondary cause, such as the post-
phlebitic syndrome.
Clinical exclusion criteria. Exclusion criteria
were chosen to safeguard patients and to eliminate
conditions that would add bias to the study. Patients
were required to be older than 18 years and neither
pregnant nor planning further pregnancies. Patients
with proximal iliac vein occlusion (outflow disease)
were excluded, as were those with primary venous
valvular disease who, in the opinion of the operating
surgeon, would be better served by valvuloplasty.
Patients with superficial or perforator venous insuf-
ficiency were not acceptable candidates. Also exclud-
ed were patients with significant preexisting co-mor-
bid conditions, including congestive heart failure,
peripheral arterial insufficiency, vasculitis, known
coagulopathy, contraindications to chronic anticoag-
ulation (heparin or warfarin), morbid obesity (more
than 175% of ideal body weight), and active infec-
tion with sepsis. Furthermore, patients unwilling or
unable to comply with postoperative follow-up visits
and examinations were excluded from this study.
Preoperative evaluation. A routine history and
physical examination was performed to evaluate and
prepare a patient for possible valve transplantation.
Specific patient demographics recorded included
age, sex, the presence of hypertension (140/90 mm
Hg or higher or on medications), diabetes mellitus,
hyperlipidemia (history with or without medica-
tion), a history of coronary artery disease, the New
York Heart Association (NYHA) classification, and a
smoking history (past, present, never). Pertinent
chronic venous disease demographics included any
history of deep venous thrombosis, leg edema, past
or present venous ulcers, and the number of ulcer
recurrences experienced in the last 5 years. The use
of nightly and intermittent leg elevation, compres-
sive support (with degree of compression), and a
history of earlier surgery to correct superficial, per-
forator, or deep venous insufficiency were recorded.
Preoperative testing. Each of the following
tests were performed in all patients. A venous duplex
scan evaluated venous occlusive disease, especially
earlier deep venous thrombosis (recannalization,
collaterals, etc). It was used to assess venous reflux,
as per each institution’s standards, generally by using
a reflux time of more than 0.5 seconds to separate
abnormal from normal results.19 It served as a base-
line for postoperative evaluation of allograft patency
and competence. It allowed determination of the
donor vein diameter, to match that of the recipient
vein. An ascending venogram more clearly defined
the venous anatomy and also helped determine the
optimal recipient bed and diameter of donor allo-
graft. A descending venogram determined the pres-
ence and location of venous valves and the degree of
venous reflux.20 Only grade-3 and -4 reflux were
considered to be of surgical significance.20 An ankle-
brachial index was obtained to establish the absence
of peripheral vascular disease (0.9 or higher was con-
sidered acceptable). A blood type was required to
allow proper ABO matching. A hypercoagulable
work-up was required in all patients with a previous
history of venous thrombosis, in an attempt to con-
form to the exclusion criteria established, and
included levels of antithrombin III, activated protein
C, protein S, anticardiolipin and antiphospholipid
antibody, lupus anticoagulant, prothrombin time,
activated partial thromboplastin time, and a platelet
count.
One or more of the following venous hemody-
namic tests confirmed that reflux was the major dis-
order in each patient. Tests were repeated when the
transplant was successful to determine a meaningful
clinical outcome score. The study was not required
when the allograft failed. Venous refilling time
(VRT) was assessed by means of photoplethysmog-
raphy. Intravenous pressure measurements were a
means of providing a measure of venous filling time
(VFT), ambulatory venous pressure (AVP), and
VRT.21 A VRT less than 20 seconds was considered
abnormal. A number of venous hemodynamic para-
meters, including the calf pump, obstruction, and
insufficiency, were evaluated by means of air plethys-
mography. A quantitative measure of overall venous
reflux was provided by means of the venous filling
index (VFI90), and less than 2 mL/sec was consid-
ered to be a normal reading.22 A significant effect, as
evaluated by means of air plethysmography, was con-
sidered to be a change by one or more categories
(mild, moderate, severe), as defined for each nonin-
vasive laboratory test involved, and was then used in
clinical outcome scoring instead of the AVP or
VRT.18
The CEAP18 classification was determined by
means of the clinical examination and history (clini-
cal grade and etiology) and by means of venography,
with support from duplex scanning and plethysmo-
graphic or intravenous pressure studies (anatomy
and pathophysiology).
Because only a single valve transplant was to be
evaluated, the transplant was located below all sig-
nificant thigh reflux. When the profunda system was
competent, the valve was placed in the superficial or
popliteal vein. When the profunda system was
incompetent, the allograft transplant was placed in
the most normal vein (distal superficial femoral or
popliteal) below all reflux, as demonstrated by
means of descending venography. The diameter of
the donor vein was matched to the recipient by mea-
suring the recipient vein diameter with venography,
duplex scanning, or both in the most normal-
appearing segment determined to lie below all
venous reflux.
Operative management
The specific surgical technique was left to the
discretion of the surgeon, but the general consensus
was to use an interrupted technique with nonab-
sorbable suture (5-0 to 7-0 prolene). Sufficient
recipient vein was removed for optimal fit, and the
length of the donor vein was at least three times its
diameter to avoid injury to the venous cusps when
performing the anastomosis. Post-thaw donor valve
competence was confirmed by means of retrograde
distention of the vein with a syringe filled with
heparin solution, aided by gravity drainage. Further-
more, at the completion of the operation, the clini-
cal strip test was performed. The use of an adjuvant
dAVF was left to the discretion of the operating sur-
geon. Documentation of the site of implantation
(superficial femoral vein or popliteal vein), length of
donor vein used, and the use of an adjuvant dAVF
was required. All patients were given heparin (frac-
tionated or low-molecular weight) before and dur-
ing implantation, and it was continued until ade-
quate conversion to warfarin anticoagulation was
made. Oral anticoagulation was continued for the 6
months of the study protocol.
Cryopreserved allograft. Superficial femoral
vein allografts with competent valve(s) were
removed from qualified donors by organ procure-
ment organizations and regional tissue banks and
sent, with consent, to CryoLife (Kennesaw, Ga).
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The vein was aseptically dissected of surrounding fat,
and any leaking branches were sutured for hemosta-
sis. The most proximal valve (when multiple valves
were present) was tested for competence by means
of a hydrostatic pressure device to 125 mm Hg to
confirm competence. The vein allograft was then
incubated in a tissue culture medium with an antibi-
otic, placed in a cryoprotectant, and controlled-rate
frozen to –135°C or colder. The allograft was
shipped at –70°C and thawed within 72 hours for
surgical use. Once thawed by a four-step protocol,
the tissue handled as any human vein.
Postoperative assessment
Any adverse event was recorded, whether or not it
was directly related to the valve transplantation. This
included serious medical events, reoperations, the
need for allograft explant, and death. Aneurysm for-
mation, cusp degeneration, immunologic reaction,
and tears or perforations in the donor allograft, either
intraoperatively or postoperatively, were recorded.
Wound complications, such as dehiscence, cellulitis,
and seroma formation, were documented. Deep
venous thrombosis with or without emboli, recurrent
venous ulcers after having been healed once, or other
problems also required documentation.
Scheduled patient visits were 1, 3, and 6 months
after surgery and included a history, physical exami-
nation, and a venous duplex study of the valve site.
The primary end point of allograft valve patency and
competence was determined by means of serial
duplex scanning. A descending venogram scheduled
at 1 month was used as a means of confirming the
duplex findings. Venous hemodynamic studies were
obtained at 1 and 6 months when required by con-
tinued valve function. The secondary end point of
clinical outcome was determined by means of the
history, physical examination, and venous hemody-
namic study(ies).18
Data analysis/statistical methods
Data from all participating centers were entered
into a database and pooled for analysis. Recipient
demographics and the CEAP classification were
defined by means of descriptive statistics. The allo-
graft valve performance and patient survival were
evaluated by means of statistical actuarial methods to
provide cumulative graft patency (%), overall free-
dom from valve incompetence (%), and overall
patient survival (%). Complications, adverse events,
and explant data were summarized.
RESULTS
Eleven patients were recruited for this study. A
63-year-old man was considered non-compliant
because he discontinued his anticoagulant therapy
shortly after surgery and was found to have an allo-
graft occlusion 50 days postoperatively. The allograft
had been placed in the popliteal vein and was docu-
mented to be occluded by means of a duplex scan
and ascending venography, and the patient was
asymptomatic, with a healed ulcer. A patient was
recruited to replace him in the study. The other pro-
tocol violation involved a 37-year-old man who was
found to have a protein S deficiency, only after an
occlusion was discovered 86 days after implantation.
The valve was in the superficial femoral vein, and the
patient was not clinically improved. Because this
information was not known until late in the study, a
replacement patient was not recruited. The nine
remaining patients form the basis for this phase I fea-
sibility study.
Most patients were men (7 of 9), and their aver-
age age was 56.8 years (range, 36 to 77 years). The
Table I. Specific demographics of patients with venous disease involved in this study
Hemodynamic
Earlier evaluation
Affected Earlier venous Ulcer Ulcer VRT VFI90
Patient side DVT surgery Present Past size (seconds) mL/sec
GC L no yes no yes N/A 12 6.0
GP R yes yes yes yes 10 sq cm 4 3.0
FT L yes yes yes yes 8 sq cm 10 –
ML L yes yes yes yes 2 sq cm 3 1.5
WW L yes yes yes yes 4 sq cm 0 26.0
SC L yes no yes yes Entire lower leg 29 5.5
EB L no* no yes yes 16 sq cm – –
GS L yes yes no yes N/A 1 4.5
JB L yes yes no yes N/A 10 9.4
*Venogram consistent with old DVT (recannalization of superficial femoral vein).
DVT, Deep venous thrombosis; VRT, venous refilling time; VFI90, venous filling index; N/A, not applicable.
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patients were quite healthy, with the exception of
their venous disease. Only one patient had a NYHA
class greater than 1 (NYHA class 2); one patient had
type 1 diabetes mellitus; and only 22% of patients
were hypertensive, smokers, past smokers, and/or
had a past history of coronary artery disease.
The patients’ venous disease demographics are
presented in Table I. In addition, all patients had
complaints of edema, skin changes consistent with
chronic venous disease, and used leg elevation to
alleviate some of the edema and discomfort of the
disease. Of those patients with ulcers, four patients
had ulcers that had been continually present for the
last several years, whereas the other two patients had
ulcers that recurred three or more times in the same
period. In those patients with a healed ulcer, each
patient had experienced three or more recurrences
in the previous 5 years. One patient (EB) did not use
compressive therapy because of severe discomfort,
but all other patients used it at a compression level
of 30 mm Hg or greater. Table II further classifies
the patients by means of the CEAP method. The
patients can be defined, in general, as C5-6,S ES AD
PR with some outliers. The one case of superficial
reflux was suggested by means of venographic mild
greater-saphenous reflux, which was not considered
significant and did not alter venous hemodynamic
studies to any degree. The one case of isolated per-
forator reflux was located in the lower calf, below all
deep disease, and appeared mild by means of duplex
study. The finding of old deep venous occlusive dis-
ease (recannalization, etc) by means of duplex scan-
ning or venography did not translate into hemody-
namic abnormalities, but it is included to help define
the patients being treated.
Some specifics of the allograft operation are pro-
vided in Table III. The diameter of the donor allo-
graft was 7 to 12 mm, and the length averaged 4.6
cm (range, 3 to 7 cm). One competent venous valve
was documented in each segment, but in two cases,
the surgeon felt the valve was moderately incompe-
tent after thawing and performed a bench valvulo-
plasty. The optimal site of implant was the popliteal
vein in four cases and the superficial femoral vein in
five cases. In two cases, an adjuvant dAVF was con-
structed to improve venous flow. A large diameter
(0.5 cm) dAVF was constructed simultaneously with
and just distal to the allograft transplant in one case
with a planned ligation in 6 weeks. The other was
constructed at the time of an allograft salvage opera-
tion at a distant location (posterior tibial artery to
vein) and allowed to function indefinitely. This sal-
vage operation included thrombectomy, valvuloplas-
ty, and saphenopopliteal bypass grafting to correct an
obstruction that became evident at a location of a
failed autogenous venous valve transplant. Operative
complications were observed in four cases. There
were two early occlusions, one of which was correct-
ed surgically with the use of a dAVF and is the only
case involving secondary patency. The other case 
of thrombosis was associated with a seroma that
involved the transplant site, as documented at the
time of seroma drainage. There were two other cases
of seroma formation not involving the allograft, and
in one of these cases, there was an associated celluli-
tis. One seroma required surgical drainage, whereas
antibiotic treatment of the cellulitis was all that was
required in the other case.
Table IV provides data regarding the primary
end point (allograft patency and valve competence)
and the secondary end point (clinical outcome).
Included in Table IV are the follow-up studies at 6
months to determine the valve’s effect on lower-
limb hemodynamics. All patients survived the study
without systemic sequelae. The life-table primary
and secondary cumulative graft patency rates are
Table II. CEAP classification of venous insufficiency
Pathophysiologic 
Clinical Anatomic (deep disease)
Patient Grade Symptoms Etiologic Deep Other Reflux Obstruction
GC 5 yes P yes S yes
GP 6 yes S yes yes yes
FT 6 yes S yes yes yes
ML 6 yes S yes yes yes
WW 6 yes S yes yes yes
SC 6 yes S yes yes yes
EB 6 yes S yes P yes
GS 5 yes S yes yes yes
JB 5 yes S yes yes
S, Superficial reflex; P, perforator reflex.
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shown in Fig 1. Fig 2 provides primary and sec-
ondary freedom from valve incompetence results.
The only allograft thrombosis occurring after the
30-day perioperative period was associated first, at 2
months, with a tibial deep venous thrombosis after
the patient sustained a traumatic metatarsal fracture.
The allograft was open and competent at 3 months.
After a urologic consult for hematuria, the patient
was instructed to discontinue his anticoagulants, and
within 2 months, the allograft occluded. Two recur-
rent ulcers occurred in patients with a duplex-con-
firmed patent and competent valve. In one case,
progressive arterial disease resulted in very poor dis-
tal perfusion (40 mm Hg) at 4 months of follow-up,
and an ulcer recurred. Balloon angioplasty of the
superficial femoral and popliteal arterial stenoses
improved the pressure to 90 mm Hg, but at 6
months, the ulcer was still not healed. All remaining
patients were instructed on and, except for one
patient (patient refusal), were using elevation and
compression stocking support after the operation.
The compression stocking support averaged 30 mm
Hg, whereas three patients were using Circard com-
pression.
DISCUSSION
The patients’ general demographics are a reflec-
tion of the rather stringent exclusion criteria estab-
lished for this protocol. The patients were generally
middle-aged men with few risk factors for athero-
sclerosis. These criteria were established to minimize
the effect of systemic conditions (heart failure, coag-
ulopathy, sepsis, lower-extremity arterial disease) on
mortality, healing, and valve function. The desire




Diameter Length Blood type Thrombosis Cellulitis Seroma
Patient (mm) (cm) Donor Recipient Site Adjuvant (days)
GC 9-9 4 O O Pop dAVF† 20‡
GP 11-11 4 A A Pop
FT 7-12 3 A A Pop dAVF
ML 9-10 4 A A SFV* 3 3
WW 9-12 7 A A SFV
SC 9-10 4 O B SFV* 3 §
EB 9-11 3 O O Pop
GS 8-9 5 O O SFV
JB 8-9 7 O O SFV 29 3 i
*Valvuloplasty of allograft performed.
†Only after thrombectomy and to improve 2-degree patency.
‡Reopened surgically.
§Seroma drained; did not involve allograft.
iSeroma drained; did involve allograft.
Pop, Popliteal; SFV, superficial femoral vein; dAVF, distal arteriovenous fistula.
Table IV. Clinical outcomes after cryopreserved allograft venous valve transplantation
3 months 6 months
Allograft Allograft Hemodynamics
Clinical
Patient Patent Competent Ulcer healed Patent Competent VRT (seconds) VFI90 (mL/sec) outcome Ulcer healed
GC yes* yes* N/A yes* yes* – 5.1 +2 N/A
GP yes yes yes yes yes – – 0‡ no§
FT yes yes 50% yes† no 7 – 0 no
ML yes yes yes yes yes – – 0 no§
WW yes yes yes no no – – +1 yes
SC yes yes 70% yes yes 40 0.9 +2 85%
EB no no yes no no – – +1 yes
GS yes yes N/A yes yes 5 1.4 +2 N/A





JOURNAL OF VASCULAR SURGERY
860 Dalsing et al November 1999
was to determine how the cryopreserved venous
valve transplant would perform in a rather challeng-
ing venous system, while eliminating extraneous
variables.
The criteria for inclusion defines a severely dis-
abled patient population and translated practically
into all participants having or having had recalcitrant
venous ulcerations (C5-6,S). The underlying cause
was generally the postphlebitic syndrome (89%),
which was also reflected by most patients having
areas of old scarring (narrowing, recannalization,
etc) in the affected venous system, as assessed by
means of duplex imaging and ascending venography
(67%). Such patients were chosen to participate as
long as the supporting diagnostic studies (duplex,
descending venography, plethysmethographic stud-
ies, etc) confirmed venous insufficiency to be the
major problem. Such a damaged venous conduit
would pose practical surgical dilemmas, but such
patients were considered acceptable candidates
because they represent those patients most in need
of this type of venous transplant. Earlier reports of
venous valve transplantation for the treatment of
chronic deep venous insufficiency have been criti-
cized because more than one component (deep,
superficial, perforator) of the lower-extremity
venous system was defective, making it difficult to
discern whether operative repair of one or the other
was most important in the ultimate outcome. To
eliminate multiple variables as a concern, we elimi-
nated patients with iliac venous occlusion on the side
that was considered for transplantation (outflow dis-
ease) and patients with major distal occlusive disease.
Similarly, superficial disease, perforator disease, or
both could not exist or must have been treated
before inclusion in this study. Furthermore, the goal
of this study was to evaluate only one cryopreserved
valve in each patient. The decision was made, there-
fore, to transplant only one valve below all reflux.
Certainly, the popliteal location above or below the
knee is acceptable and is championed by some
authors,6,23-25 but a superficial femoral vein location
would be acceptable when the profunda system is
competent.5,26-28 Profunda insufficiency can result
in recurrent symptoms when superficial femoral vein
incompetence is corrected alone.5,27,28 With these
established criteria, the results in this manuscript
specifically reflect the effect of a single cryopreserved
venous valve transplant for the surgical treatment of
isolated deep venous insufficiency. In 78% of these
patients, previous surgery was required to establish
deep venous insufficiency as the remaining critical
hemodynamic problem, as confirmed by means of
an abnormal VRT, VFI90, or both.
Even with these exclusion criteria in place to
limit variability, other factors were not controlled, so
Fig 1. Actuarial primary and secondary patency rates for
cryopreserved venous valve allografts transplanted as valve
substitutes into the lower extremity venous system of
patients with severe isolated deep venous insufficiency.
Note that error bars are greater than 10% for all intervals.
Fig 2. Actuarial primary and secondary competency rates
for cryopreserved venous valve allografts transplanted into
the lower extremity of patients with isolated and severely
symptomatic deep venous insufficiency. Note that error
bars are greater than 10% for all intervals.
patient acquisition of this very select group (C4-6, E,
A0, PR) was possible. Numerous hospitals and vari-
ous investigators with the liberty to decide on oper-
ative technique, particular anticoagulant use (frac-
tionated or low-molecular weight heparin), or the
use of a dAVF were all acceptable as study partici-
pant variables. Although these factors do add vari-
ability to the study, none were considered by the
design committee to be of critical importance. A
good operation performed by a skilled surgeon
using accepted diagnostic, surgical, and postopera-
tive anticoagulation (within the confines of other
study parameters) was of prime importance. How-
ever, this variability is present and must be consid-
ered when reviewing the results obtained.
The observation that two cryopreserved venous
valves required bench valvuloplasty just before trans-
plantation is of concern. The presence of a compe-
tent valve is confirmed immediately before the cry-
opreservation process by means of gross inspection
and hemodynamic testing. Thermal fracture can
occur with careless handling during the cryopreser-
vation process, transit, or at the time of thawing.
Cryopreservation also affects smooth muscle and
connective tissue function by approximately 50%, but
venous compliance and elastic modulus, although
somewhat diminished, are generally preserved.29,30
It is conceivable that this less-severe effect of cryop-
reservative could result in laxity of the valve cusps or
dilation of the vein wall resulting in valvular insuffi-
ciency. However, the valves were repaired and trans-
planted leaving no direct histologic data. The func-
tional results have been acceptable, with both valves
patent and competent at 6 months of follow-up. This
would suggest that post-thaw valvuloplasty of cryop-
reserved venous valves is a viable option when such a
situation is encountered.
In two cases, a distal arteriovenous fistula was
constructed. In both cases, the venous valve seg-
ment remained patent for the 6-month follow-up
period. In the case of a 0.5-cm-diameter simultane-
ous dAVF with ligation in 6 weeks, the valve was
found to be patent and competent by means of
duplex scanning and descending venography 1
month after ligation. The VRT was 24 seconds.
However, at the 6-month evaluation period, a
patent vein remained, but one valve was scarred and
no longer moved on duplex imaging. The VRT
reverted to 7 seconds. The other fistula was periph-
erally placed and allowed to function indefinitely,
and the valve was patent and competent at 6
months. The large-diameter, closely positioned fis-
tula may have caused some local changes not evident
in early evaluation, but which caused a delayed valve
cusp scarring. Past experiences would not substanti-
ate a detrimental effect of even a large flow fistula on
proximal venous valves.15,31 Whether a more periph-
eral fistula with lower but continuous flow may be
more clinically applicable or whether a dAVF is ben-
eficial at all for early patency cannot be answered by
this study.
A postoperative seroma occurred in 33% of our
patients. This complication has been reported by
Raju in only five of 107 limbs.5 The role of lym-
phatic compensation for the malfunctioning venous
system in the management of peripheral edema has
been documented by means of a dramatic increase in
lymphatic flow in patients early in the disease, with
signs of later damage.32 In either case, any surgical
lymphatic disruption without adequate ligation
could result in the formation of a seroma. This prob-
lem occurred only when operating on the superficial
femoral vein, a situation akin to its presentation after
arterial bypass grafting operations in the same
area.33 Luckily, the presence of a seroma did not
necessarily translate into valve thrombosis. A con-
scious effort to ligate lymphatic channels should be
made to prevent this surgical complication.
The operation is safe, resulting in no mortality or
limb- or life-threatening surgical or medical compli-
cations. Although deep venous thrombosis occurred
in the three protocol patients who experienced a
valve occlusion and in the two protocol violations, no
patient experienced extensive deep venous thrombo-
sis or signs of pulmonary emboli. Anticoagulant ther-
apy probably explains this result in those patients
who were treated with it, whereas a protracted slow
occlusion of the valve with adequate time for collat-
eral development might explain this result in the
other two patients.
The primary goal of this study was to evaluate
the ability of cryopreserved venous valves to remain
patent and competent in this patient population. Is
a primary patency rate of 66.7% and freedom from
valve incompetence of 55.6% at 6 months an accept-
able result in this patient population? As described
earlier, these patients have severe symptomatic deep
venous disease, with no remaining therapeutic
options for symptom relief. Two patients had even
failed an earlier autograft venous valve transplant.
Because there are no other clinical series of allograft
venous valve transplantation available for compari-
son, the standard becomes upper-extremity venous
valve autografts to the lower-limb insufficient
venous system. The difficulty with such a compari-
son is that direct evidence of the valve status is not
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always reported. Direct duplex evaluation of the
valve transplant was available in the Tufts series; all
valves were patent and competent at 2 years.23 Only
six of 11 patients in the Atlanta series had compe-
tency confirmed by means of descending venogra-
phy at 6 or more months after transplantation, and
all valves were found to be competent.24 Thirty-one
of 71 valve transplants were venographically evaluat-
ed by Taheri et al,6 with one occluded and two
incompetent valves found, for a failure rate of 9.7%,
but the length of follow-up is unclear. Raju’s series
evaluated 44 of 54 axillary vein valve transplants
with serial duplex scanning follow-up, and he
reported a 6-month valve competency rate of
approximately 50%.26 His series is slightly different
from the others in that a prosthetic sleeve was placed
around the valve transplant to prevent later dilation.
The Sweden experience reported a 25% axillary vein
valve transplant failure rate (two occlusions, one
incompetence) in 12 limbs at 6 months, with eight
of 11 valves failing within 6 to 48 months.27 Finally,
Kistner and associates report that two of two valve
transplants were either competent or had only minor
reflux after 4 years or longer of follow-up.28 These
results certainly run the gamut. As with most
instances of vascular surgical repair in low-flow sys-
tems, autografts generally perform most favorably.
However, this review of the literature would suggest
that the early results of a cryopreserved venous
valve, as reported in this study, would make it an
acceptable alternative when no autologous tissue is
available.
There are several theoretical reasons to help
explain why cryopreserved venous valve transplants
might fail. Two failed early with adequate anticoag-
ulation, which would suggest a technical error.
However, the one case operatively approached for
secondary patency demonstrated thrombus in the
cusps and on the vein wall, but no misplaced sutures
nor technical narrowing. The clot was mechanically
removed, a dAVF was constructed and aggressive
anticoagulation was undertaken, and the valve func-
tioned throughout the remainder of the study. The
other two valve failures presented as an occlusion
within a few months of discontinuing anticoagula-
tion in one case and as a single valve cusp thickening
with loss of movement in the other. As shown clini-
cally when using venous allografts in the arterial sys-
tem, rejection may be a concern.34 Cytotoxic T-cells
could result in valve-cusp or vein-wall damage,
endothelial cells could be destroyed, and/or a
humoral immune response could activate the com-
plement cascade.34 Certainly, endothelial cells are
often lost in the first 10 days after allograft trans-
plantation into the vascular system of experimental
animals, with reendothelialization occurring within
the next 6 months.35,36 However, not all allografts
are so challenged by significant rejection, leading
one to conclude that local injury, hypercoagulability,
or stasis may still be the causative factor or factors in
some cases.34 Duplex evaluation of valves in the
absence of or before failure demonstrated cusps that
were thin and rapidly responsive to hemodynamic
change. In fact, in the single case of valve incompe-
tence in the otherwise patent allograft, the remain-
ing valve cusp appeared grossly normal by means of
duplex evaluation. This would make one think that
whatever process is ongoing must be subclinical until
such time as an extenuating event intervenes (eg, dis-
continuation of anticoagulants). Interestingly, one of
the protocol-violation patients also occluded, but
only after discontinuing anticoagulant therapy.
Whatever the underlying causes, long-term anticoag-
ulation appears useful for continued valve function
and aids in the prevention of extensive deep venous
thrombosis if the allograft fails. The issue of rejection
is a valid concern, but our data can shed no further
light on this topic. Furthermore, because only one
valve failed in the absence of allograft occlusion, it
would appear that allograft valves generally remain
competent when patency is maintained. Also, the allo-
graft being studied was processed, frozen, and thawed
by only one protocol. The rate of freezing/thawing,
culture media used, use of specific cryopreservatives,
and other factors may affect results observed with 
the use of cryopreserved tissue,35,36 and the data pre-
sented cannot be extrapolated to all cryopreserved
allografts.
The secondary end point evaluates clinical impact
and, as with most series involving venous valvular
repair or transplantation, is not as conclusive as one
would have planned. Except for one case of allograft
thrombosis, all venous ulcers, in the six patients who
had them, had healed (n = 4) or were healing (n = 2)
at 3 months, with a competent valve in place. All
patients had fewer complaints of swelling and pain.
By 6 months, the clinical results were more difficult
to interpret. Three allografts had occluded, but the
patients were symptomatically improved. In those
cases (n = 2) where ulcers had been present, healing
had occurred, whereas in the remaining case, a dra-
matic improvement in VFI90 (9.4 to 2.6 mL/sec
post-transplant) was observed. The clinical outcome
score for the first two patients was a +1, because no
hemodynamic studies were available for awarding a
higher score. These results are consistent with those
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of other authors, who have observed that ligation
may prevent venous reflux with improved clinical
results, as long as an incompetent collateral channel
is not present.37,38 Recurrent reflux in the absence of
occlusion was observed in a single patient; the result
was reversion to the presurgery status of major reflux
and venous ulceration. The other five patients had a
competent valve in place, as proven by means of
duplex study. Two patients had significant clinical
improvement with normalization of at least one para-
meter indicative of venous reflux (VRT, VFI90, or
both). One patient had clinical improvement, but
only modest improvement in the VFI90. Recurrent
ulceration had been a problem in this patient, but did
not resurface during this study. Two patients had
competent valves, but recurrent ulceration. One case
might be explained by worsening arterial disease
(ankle pressure of 40 mm Hg) in the only patient in
this series who had diabetes mellitus. Partial correc-
tion of the arterial diseases with percutaneous angio-
plasty (ankle pressure 90 mm Hg) at 5 months of fol-
low-up had not yet resulted in ulcer healing. The
other patient did not return for venous hemodynam-
ic study, and, therefore, no further comment can be
made. Such a finding of recurrent or continued
ulceration in the face of a competent valve, although
uncommon, has been reported by other authors.26,39
Consistent with other reported series, hemodynamic
parameters of venous reflux are often not corrected
completely by a single valve transplant, even when it is
placed below all apparent reflux.5,27,28,39 Collectively,
however, these results suggest that, devoid of extenu-
ating circumstances, a patent and competent valve
translates into an improved clinical result, especially
when venous hemodynamics are improved. Recurrent
incompetence results in recurrent symptoms similar to
the preoperative state. However, allograft occlusion
not resulting in other areas of thrombosis and occur-
ring below all venous reflux may initially result in an
improvement of the patient’s clinical condition.
Recurrent symptoms caused by collateral dilation and
reflux37 were not observed during the short duration
of this study.
In conclusion, this study evaluated the use of a
single cryopreserved ABO blood type-matched
valved venous allograft, placed to correct isolated
deep venous insufficiency in patients with recalci-
trant venous ulceration. The primary aim of this 6-
month feasibility study was to determine allograft
patency and competence, with a secondary evalua-
tion of clinical outcome. Six-month actuarial results
documented an approximately 70% patency rate,
approximately 60% competency rate, and 100%
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 5 Dalsing et al 863
patient survival. Overall, these results are less
impressive than the best reported results of axillary
vein transplantation, suggesting that the most
appropriate use of the cryopreserved allograft valve
is in patients with no autograft option. The clinical
outcome was generally improvement, with freedom
from ulcer recurrence in six of nine patients. Long-
term anticoagulation appears to be helpful in main-
taining valve function and preventing extensive
thrombosis when allograft failure occurs. Valve
patency and competence is desirable for optimal
results, but, in early evaluation, isolated allograft
thrombosis may prevent reflux, resulting in clinical
improvement. Recurrent reflux results in recurrent
symptoms.
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DISCUSSION
Dr Alan B. Lumsden (Atlanta, Ga). Dr Dalsing and his
colleagues have presented a stimulating and somewhat
controversial study. The enormous clinical need for an
effective valve replacement and the practical appeal of cry-
opreserved superficial femoral vein valves cannot be dis-
puted. Valves could potentially be available off-the-shelf.
We can get various lengths of superficial femoral vein, vari-
able numbers of valves; size matching can be achieved, and
as you have heard, the clinical testing that is required to
obtain these grafts is ABO typing. There is essentially no
earlier human data available, so this is an important report.
Indeed, the only earlier venous data on cryopreserved
femoral veins also comes from Dr Dalsing’s laboratory,
from his greyhound model, which was followed up for 2
months, showing patency. There is significantly more data
available on the use of this kind of conduit in the arterial
literature, in which cryopreserved saphenous vein has been
widely used, but it has been used very much as a niche
conduit, usually in a situation in which we are presented
with limb threat, in which there is no alternate conduit
available, and in which long-term patency generally is not
expected, nor has it been demonstrated. We all accept
that, in general, the superficial saphenous vein bypass
grafts have limited longevity.
We have also used this conduit as an arteriovenous
access graft and would confirm the ease of handling of the
superficial femoral vein and the suturability reported by
Dr Dalsing. But again, this is being done in a very special
situation, in which the long-term patency is really not
anticipated and in which graft failure is unlikely to be of
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significant clinical consequence. Neither of these circum-
stances essentially exists when we use superficial femoral
vein as a venous conduit. Usually, the disease for which it
is being used is not immediately limb threatening, and fail-
ure could result in either limb threat or exacerbation of
limb threat, or could even be life threatening.
One persistent question that hovers over the use of
cryopreserved vascular tissue is that of patient sensitiza-
tion. Why do these grafts fail, and what is the role of the
cytotoxic T cells that are generated? It has been clearly
demonstrated, including in the use of saphenous veins,
that endothelial cells persist and that this can elaborate an
immune reaction, so that even if we can potentially con-
trol the up-front problems of thrombosis, the long-term
sequelae of potential sensitization of these patients are
largely unknown. As Dr Dalsing said, the objective here—
this is really a phase 1 study—is to determine safety and
feasibility and to determine if cryopreserved venous valve
segments will remain patent or competent in the short
term. It is obvious that this is a very highly selected group
of patients, with no superficial or perforator incompetence
and no significant venous obstruction. It’s the ideal model
for testing whether this valve has efficacy.
They initially enrolled 11 patients in this trial, but two
patients were subsequently excluded from analysis, one
because he was noncompliant with the Coumadin and the
other because he had a protein S deficiency. These are the
sort of day-to-day problems we have to deal with in
patients in whom we would be using a graft such as this.
The authors’ final analysis is based only on nine patients.
They have demonstrated that the procedure was associat-
ed in this study with an approximate 44% complication
rate, looking at the number of seromas and cellulitis, and
that does not include thrombosis of the conduit as a major
complication. Primary patency, again in nine patients, not
the overall 11 patients, was only 67% at 6 months, and pri-
mary valve competency was approximately 56%. As Dr
Dalsing intimated, it was safe. None of these patients sus-
tained a pulmonary embolism. It is somewhat surprising
that there were only six patients who actually had measur-
able ulcers, and three of those six patients did have some
recurrence or non-healing of their ulcers despite having a
functional valve demonstrated. They were both patent and
competent, and I think that deserves some speculation.
In summary, despite this well-conducted study with
premiere venous investigators, we are left with a series of
data that we are not entirely sure how to use. I’m not
entirely sure what to deduce or what we should do in the
next step. I am trying to figure out what we should do
with this data and what the potential implications are for
moving to a phase 2 study, so I address the following
questions to Dr Dalsing.
How were the conduits selected? You intimated that
you tried to match the size of the recipient with the donor
vein. How did you actually measure the diameter of the
recipient vein? Was this based on the duplex measure-
ments or the venographic measurements? Given the not-
insignificant thrombosis rate, would you change either the
operative technique or the anticoagulation regimen that
you used? And could you comment on the extent of
thrombosis that occurred when the device failed? Given
that all cryopreserved vascular conduits have limited dura-
bility, how do we really manage to justify the use of such
a graft in a condition that is really not limb threatening
and in which graft failure may exacerbate the underlying
problem for which it has been applied? If we do go to a
phase 2 protocol, how would you refine the patient-selec-
tion criteria or any of the techniques that were involved in
the study? Finally, do you think that immunosuppression,
which has been intimated in some of the arterial data, has
a potential role in prolonging conduit patency?
I would like to thank Dr Dalsing for providing the
manuscript. It is excellently written. I think that the study
has been very well done and poses many questions that
need to be addressed. I would like to thank the Society for
the privilege of discussing this paper.
Dr Michael C. Dalsing. Thank you, Al. I will try to go
through the questions in order.
The way that we determined the proper size-match was
to use venographic data, with a 20% diameter decrease,
because of the method in which venograms are performed,
or by means of a direct match with duplex scanning. So, we
actually tried to end up with the same diameter match.
About what I would do to possibly improve the
results: I have always had the impression, based on exper-
imental work, that you might need to use a temporary
arteriovenous fistula, but I don’t have sufficient data in
this paper to tell you if that is true. Long-term anticoagu-
lation is mandatory, based on these nine patients plus
some data we have about non-protocol grafts that have
failed. Once anticoagulation is discontinued, the allografts
generally thrombose within a few months.
When the device does fail, the extent of clotting is
generally only at the graft site, which probably explains the
low risk of pulmonary emboli and the lack of worsening
symptoms after failure. In fact, in our experience, graft
occlusion generally resulted in improved symptoms rather
than symptom exacerbation.
How would we revise the protocol if we went to a
phase 2 study? I think that the only time one would con-
sider using this type of material would be in the end-stage
patient who really has lifestyle-disabling problems, and I
think that is the type of patient we tried to capture in this
study. In that respect, I probably wouldn’t change the pro-
tocol for a phase 2 study. I would look for those patients
who have no other options. I think in some cases we look
at venous disease as an all-or-none phenomenon when it
comes to treatment. In fact, in those patients who have
postphlebitic syndrome, I think we see the same problems
that we have observed with arterial surgery. We generally
palliate, using some type of autogenous reconstruction that
will fail eventually. Having run out of autogenous tissue,
we use an alternative graft. Chronic venous insufficiency
does not usually result in limb loss or death. However, for
the walking wounded with chronically draining ulcers, any
help is often viewed as a godsend. Once autogenous valve
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repair has run its course, a cryopreserved valve may help
the patient to function for another few years. In our expe-
rience, failure of the graft with occlusion is not sympto-
matically a problem, and so, even with failure, a few more
years of symptomatic relief can be expected.
Rejection may certainly be a factor in the failure of
these grafts, if the arterial graft literature is applicable.
Immunosuppression, if ever useful, must be at a degree
that would not hinder venus ulcer healing, but would pro-
tect the allograft. Probably some type of Cytotoxic T-cell
immunosuppressive agent will be required. At this time, I
have no data to suggest how this factor may play out in
clinical practice.
Thank you.
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